These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 19995705)

  • 1. Serum cathepsin K and cystatin C concentration in patients with advanced non-small-cell lung cancer during chemotherapy.
    Naumnik W; Niklińska W; Ossolińska M; Chyczewska E
    Folia Histochem Cytobiol; 2009; 47(2):207-13. PubMed ID: 19995705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of HMGB1, survivin, and VEGF in patients with advanced non-small cell lung cancer during chemotherapy.
    Naumnik W; Nilklińska W; Ossolińska M; Chyczewska E
    Folia Histochem Cytobiol; 2009; 47(4):703-9. PubMed ID: 20430742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer.
    Werle B; Kotzsch M; Lah TT; Kos J; Gabrijelcic-Geiger D; Spiess E; Schirren J; Ebert W; Fiehn W; Luther T; Magdolen V; Schmitt M; Harbeck N
    Anticancer Res; 2004; 24(6):4147-61. PubMed ID: 15736466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
    Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
    Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer.
    Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E
    Cancer Invest; 2006 Oct; 24(6):576-80. PubMed ID: 16982461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of VEGF-C, VEGF-D, and sVEGF-R2 in patients with lung cancer during chemotherapy.
    Naumnik W; Izycki T; Swidzińska E; Ossolińiska M; Chyczewska E
    Oncol Res; 2007; 16(9):445-51. PubMed ID: 18074680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of IGF-I and IGF-II in patients with lung cancer during chemotherapy.
    Izycki T; Chyczewska E; Naumnik W; Talalaj J; Panek B; Ossolinska M
    Exp Oncol; 2004 Dec; 26(4):316-9. PubMed ID: 15627066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunochemical analysis of cathepsin B in lung tumours: an independent prognostic factor for squamous cell carcinoma patients.
    Werle B; Lötterle H; Schanzenbächer U; Lah TT; Kalman E; Kayser K; Bülzebruck H; Schirren J; Krasovec M; Kos J; Spiess E
    Br J Cancer; 1999 Oct; 81(3):510-9. PubMed ID: 10507778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications.
    Tumminello FM; Flandina C; Crescimanno M; Leto G
    Biomed Pharmacother; 2008 Feb; 62(2):130-5. PubMed ID: 17728092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cysteine proteinase cathepsin H in tumours and sera of lung cancer patients: relation to prognosis and cigarette smoking.
    Schweiger A; Staib A; Werle B; Krasovec M; Lah TT; Ebert W; Turk V; Kos J
    Br J Cancer; 2000 Feb; 82(4):782-8. PubMed ID: 10732746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC.
    Jantus-Lewintre E; Sanmartín E; Sirera R; Blasco A; Sanchez JJ; Tarón M; Rosell R; Camps C
    Lung Cancer; 2011 Nov; 74(2):326-31. PubMed ID: 21481963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
    Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M
    Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of sFas and sFasL during chemotherapy of lung cancer.
    Naumnik W; Izycki T; Ossolinska M; Chyczewska E
    Exp Oncol; 2007 Jun; 29(2):132-6. PubMed ID: 17704746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the clinical significance of serum HE4 levels in lung cancer and pulmonary tuberculosis.
    Liu W; Yang J; Chi PD; Zheng X; Dai SQ; Chen H; Xu BL; Liu WL
    Int J Tuberc Lung Dis; 2013 Oct; 17(10):1346-53. PubMed ID: 24025389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of microwave ablation or its combination with whole-body chemotherapy on serum vascular endothelial growth factor levels in patients with stage IIIB/IV NSCLC.
    Sun YH; Song PY; Guo Y; Pang M; He WN; Zhang WH; Sheng LJ
    Genet Mol Res; 2015 Aug; 14(3):10015-25. PubMed ID: 26345938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum ferritin is elevated in advanced non-small cell lung cancer patients and is associated with efficacy of platinum-based chemotherapy.
    Shi HB; Li XD; Jiang JT; Zhao WQ; Ji M; Wu CP
    J Cancer Res Ther; 2014; 10(3):681-5. PubMed ID: 25313760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of angiopoietin-1, angiopoietin-2, and their receptor tie-2 in patients with nonsmall cell lung cancer during chemotherapy.
    Naumnik W; Chyczewska E; Ossolinska M
    Cancer Invest; 2009 Aug; 27(7):741-6. PubMed ID: 19340656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer.
    Tas F; Duranyildiz D; Soydinc HO; Cicin I; Selam M; Uygun K; Disci R; Yasasever V; Topuz E
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):721-5. PubMed ID: 17554539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response.
    Vollmer RT; Govindan R; Graziano SL; Gamble G; Garst J; Kelley MJ; Christenson RH
    Clin Cancer Res; 2003 May; 9(5):1728-33. PubMed ID: 12738727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients.
    Chen Q; Fei J; Wu L; Jiang Z; Wu Y; Zheng Y; Lu G
    Oncol Lett; 2011 Jul; 2(4):693-699. PubMed ID: 22848251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.